Overview

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status:
Recruiting

Trial end date:
2036-09-01

Target enrollment:

Participant gender:

Summary

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

Phase:

Phase 1

Details

Lead Sponsor:

Poseida Therapeutics, Inc.